Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARDX Stock Forecast 2025-2026
$5.98
Current Price
$1.45B
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ARDX Price Targets
+167.6%
To High Target of $16.00
+83.9%
To Median Target of $11.00
+33.8%
To Low Target of $8.00
ARDX Price Momentum
+3.1%
1 Week Change
+5.8%
1 Month Change
+4.5%
1 Year Change
+17.9%
Year-to-Date Change
-11.8%
From 52W High of $6.78
+86.3%
From 52W Low of $3.21
📊 TOP ANALYST CALLS
Did ARDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ardelyx is one of their latest high-conviction picks.
Latest ARDX Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, ARDX has a bullish consensus with a median price target of $11.00 (ranging from $8.00 to $16.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $5.98, the median forecast implies a 83.9% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Christopher Raymond at Piper Sandler, suggesting a 33.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARDX Analyst Ratings
10
Buy
1
Hold
0
Sell
ARDX Price Target Range
Low
$8.00
Average
$11.00
High
$16.00
Current: $5.98
Latest ARDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 4, 2025 | Piper Sandler | Christopher Raymond | Neutral | Maintains | $10.00 |
| Nov 3, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $11.00 |
| Oct 31, 2025 | TD Cowen | Joseph Thome | Buy | Maintains | $10.00 |
| Aug 6, 2025 | Piper Sandler | Christopher Raymond | Neutral | Maintains | $9.00 |
| Aug 5, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $14.00 |
| Aug 5, 2025 | Raymond James | Ryan Deschner | Outperform | Maintains | $12.00 |
| Jun 18, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Assumes | $10.00 |
| May 2, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $10.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $15.00 |
| Mar 7, 2025 | Ladenburg Thalmann | Aydin Huseynov | Buy | Assumes | $11.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $5.50 |
| Feb 21, 2025 | Raymond James | Ryan Deschner | Strong Buy | Reiterates | $13.00 |
| Jan 27, 2025 | Piper Sandler | Christopher Raymond | Neutral | Maintains | $8.00 |
| Jan 16, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $5.50 |
| Jan 2, 2025 | Jefferies | Chris Howerton | Buy | Maintains | $8.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $5.50 |
| Nov 4, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $10.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| Aug 5, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $11.00 |
| Aug 2, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $11.00 |
Ardelyx Inc. (ARDX) Competitors
The following stocks are similar to Ardelyx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ardelyx Inc. (ARDX) Financial Data
Ardelyx Inc. has a market capitalization of $1.45B with a P/E ratio of -35.2x. The company generates $398.23M in trailing twelve-month revenue with a -14.2% profit margin.
Revenue growth is +12.3% quarter-over-quarter, while maintaining an operating margin of +4.2% and return on equity of -36.2%.
Valuation Metrics
Market Cap
$1.45B
Enterprise Value
$1.43B
P/E Ratio
-35.2x
PEG Ratio
0.4x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+12.3%
Gross Margin
+96.4%
Operating Margin
+4.2%
Net Margin
-14.2%
EPS Growth
+12.3%
Financial Health
Cash/Price Ratio
+16.7%
Current Ratio
4.4x
Debt/Equity
153.1x
ROE
-36.2%
ROA
-5.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ardelyx Inc. (ARDX) Business Model
About Ardelyx Inc.
What They Do
Develops therapies for gastrointestinal disorders.
Business Model
Ardelyx Inc. generates revenue through the development and commercialization of innovative biopharmaceutical products aimed at treating gastrointestinal and related disorders. The company focuses on unmet medical needs, with its lead product, tenapanor, targeting hyperphosphatemia in chronic kidney disease patients on dialysis, which indicates a strategic approach to address niche markets within the healthcare sector.
Additional Information
Founded in 2007 and based in Fremont, California, Ardelyx operates in a highly regulated industry, requiring extensive clinical trials and regulatory approvals. The company is committed to enhancing patient outcomes through its novel treatment solutions and plays a significant role in advancing GI treatment options, especially for patients with limited current therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
395
CEO
Mr. Michael G. Raab
Country
United States
IPO Year
2014
Website
www.ardelyx.comArdelyx Inc. (ARDX) Latest News & Analysis
Latest News
Quick Summary
Ardelyx, Inc. (Nasdaq: ARDX) presented real-world data on its drug XPHOZAH at the American Society of Nephrology's Kidney Week in Houston, highlighting its innovative approach to unmet medical needs.
Why It Matters
Real-world study results for XPHOZAH could influence market perception of Ardelyx's value and growth potential, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Ardelyx: Impressive Q3 Record Growth - Why I Buy
1 month ago
Quick Summary
Ardelyx (ARDX) is rated BUY after strong Q3 2025 results, with IBSRELA revenue up 92% YoY. Management raised 2025 guidance, citing a solid cash position and strategic patent protection.
Why It Matters
Ardelyx's strong Q3 results and raised guidance indicate solid growth potential, particularly with IBSRELA's revenue surge, enhancing investor confidence in future performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Ardelyx, Inc. (Nasdaq: ARDX) CEO Mike Raab will speak at the Wedbush Rewind ASN 2025 Conference on November 10, 2025, from 11:30 a.m. to 12:00 p.m. ET.
Why It Matters
Ardelyx's CEO participation at a key conference signals potential insights into company strategy and upcoming developments, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ardelyx, Inc. (Nasdaq: ARDX) will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025, at 4:30 pm GMT/11:30 am ET.
Why It Matters
Ardelyx's participation in a major healthcare conference highlights its potential visibility and credibility in the biopharmaceutical sector, which may influence investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Ardelyx: A Long Overdue Rally
1 month ago
Quick Summary
Ardelyx shares rose following strong Q3 results and positive guidance, indicating improved fundamentals and potential for further growth, boosting investor confidence.
Why It Matters
Ardelyx's strong Q3 results and positive guidance boost investor confidence, signaling improved fundamentals and potential for future growth, leading to increased interest in ARDX shares.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Ardelyx, Inc. (ARDX) will hold its Q3 2025 earnings call on October 30, 2025, at 4:30 PM EDT, featuring key executives and several research analysts.
Why It Matters
The earnings call provides insights into Ardelyx's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ARDX Stock
What is Ardelyx Inc.'s (ARDX) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Ardelyx Inc. (ARDX) has a median price target of $11.00. The highest price target is $16.00 and the lowest is $8.00.
Is ARDX stock a good investment in 2026?
According to current analyst ratings, ARDX has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARDX stock?
Wall Street analysts predict ARDX stock could reach $11.00 in the next 12 months. This represents a 83.9% increase from the current price of $5.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ardelyx Inc.'s business model?
Ardelyx Inc. generates revenue through the development and commercialization of innovative biopharmaceutical products aimed at treating gastrointestinal and related disorders. The company focuses on unmet medical needs, with its lead product, tenapanor, targeting hyperphosphatemia in chronic kidney disease patients on dialysis, which indicates a strategic approach to address niche markets within the healthcare sector.
What is the highest forecasted price for ARDX Ardelyx Inc.?
The highest price target for ARDX is $16.00 from at , which represents a 167.6% increase from the current price of $5.98.
What is the lowest forecasted price for ARDX Ardelyx Inc.?
The lowest price target for ARDX is $8.00 from Christopher Raymond at Piper Sandler, which represents a 33.8% increase from the current price of $5.98.
What is the overall ARDX consensus from analysts for Ardelyx Inc.?
The overall analyst consensus for ARDX is bullish. Out of 15 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are ARDX stock price projections?
Stock price projections, including those for Ardelyx Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 3:12 AM UTC